Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI

免疫肿瘤学翻译网络：RPCI 的数据管理和资源共享中心

• 批准号: 10175779
• 负责人: Alan David Hutson
• 金额: $ 84.1万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10175779
• 关键词: Address; Atlas of Cancer Mortality in the United States; Awareness; Bioconductor; Bioinformatics; Biometry; Biostatistics Shared Resource; Buffaloes; Cancer Center Support Grant; Catalogs; Clinical; Collaborations; Combined Modality Therapy; Communication; Communities; Comprehension; Comprehensive Cancer Center; Computer software; Computing Methodologies; Data; Data Analyses; Data Analytics; Data Management Resources; Databases; Dependence; Development; Drug Kinetics; Drug resistance; Education and Outreach; Ensure; Fostering; Funding; Goals; Hand; Immunooncology; Immunotherapy; Informatics; Information Technology; Infrastructure; Intranet; Logistics; Malignant Neoplasms; Manuscripts; Methods; Multiomic Data; Oncology; Performance; Policies; Positioning Attribute; Preparation; Principal Investigator; Procedures; Productivity; PubMed; Records; Reproducibility; Research; Research Design; Research Personnel; Research Project Grants; Resistance; Resource Sharing; Resources; Supercomputing; System; Text; Training and Education; Translations; United States National Institutes of Health; Universities; anti-cancer therapeutic; biobank; bioinformatics tool; cancer therapy; combat; data harmonization; data integration; data management; data sharing; data tools; data warehouse; design; drug sensitivity; expectation; experience; high standard; improved; innovation; interest; member; metabolomics; multidisciplinary; multiple omics; open source; operation; outreach; predictive marker; protocol development; quality assurance; real time monitoring; resistance mechanism; response; social media; structured data; support network; translational study; tumor; web portal

This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA- 20-052. Project Summary While several innovative and creative anti-cancer therapies have shown promising results, a significant expansion of their clinical use will require collaborative efforts to elucidate resistance mechanisms, exploit tumor sensitivity, map cancer dependence, discover new targets, identify predictive biomarkers, evaluate combination therapies, and develop real-time monitoring approaches. Leveraging cutting-edge multi-disciplinary team approaches, we will support the NCI Drug Resistance and Sensitivity Network (DRSN) to understand and combat mechanisms of tumor resistance and to exploit tumor sensitivity to anti-cancer therapies. Our strategy is to serve as an administration, communication, collaboration and analysis hub to coordinate the DRSN’s network-wide studies, focusing on reducing barriers to domain expertise, improving the productivity of DRSN investigators, maintaining a high standard for data harmonization and integration, designing and implementing rigorous analytical strategies, and fostering a collaborative and supportive research community. An experienced, multidisciplinary team has been assembled to pursue five Specific Aims: First, we will provide a centralized administration infrastructure to coordinate DRSN activities, building upon the Immuno-Oncology Translational Network (IOTN) Data Management and Resource-sharing Center (DMRC)’s well-functioning infrastructure that currently coordinates network studies under the umbrella of the NCI Cancer Moonshot initiative. Second, we will actively promote the DRSN and foster trans-consortium interactions, where we will leverage the IOTN DMRC’s demonstrable experience in Cross-Moonshot outreach and Bioconductor’s decades-long record in community-wide engagement. Third, we will provide multidisciplinary expertise to support DRSN collaborative research, leveraging four of the Roswell Park CCSG’s shared resources: Biostatistics, Bioinformatics, Data Bank and BioRepository, Bioanalytics, Metabolomics & Pharmacokinetics. Our analytic support will be armed with professional IT staff and informed by an experienced anti-cancer therapeutic researcher team. Fourth, we will develop innovative multi-omics data integration methods to enhance DRSN’s research capacity, capitalizing on the well-respected and highly-successful Bioconductor project. Fifth, we will disseminate resources developed in the DRSN to the broader community, unleashing the full potential of DRSN activities. Taken together, we envision our CC, in close collaboration with the DRSN components, will allow us to conduct highly effective and innovative translational studies to address the significantly unmet needs related to anti-cancer therapeutics, and fulfill the expectations and guiding principles of NCI Cancer Moonshot initiative.

本申请是根据非ca -特殊利益通知（NOSI）提交的